0.46 0.01 (2.22%) | 02-12 19:59 | |||||||||||||
|
|
Short term | ![]() |
|||
Mid term | ![]() |
|||
Targets | 6-month : | 0.75 | 1-year : | 0.96 |
Resists | First : | 0.64 | Second : | 0.82 |
Pivot price | 0.51 ![]() |
|||
Supports | First : | 0.36 | Second : | 0.3 |
MAs | MA(5) : | 0.43 ![]() |
MA(20) : | 0.52 ![]() |
MA(100) : | 0.77 ![]() |
MA(250) : | 1.77 ![]() |
|
MACD | MACD : | -0.1 ![]() |
Signal : | -0.1 ![]() |
%K %D | K(14,3) : | 34.9 ![]() |
D(3) : | 27.3 ![]() |
RSI | RSI(14): 42.2 ![]() |
|||
52-week | High : | 5.44 | Low : | 0.36 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ AVGR ] has closed above bottom band by 32.7%. Bollinger Bands are 25.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
If tomorrow: | Open lower | Open higher |
High: | 0.49 - 0.49 | 0.49 - 0.49 |
Low: | 0.39 - 0.39 | 0.39 - 0.4 |
Close: | 0.46 - 0.46 | 0.46 - 0.46 |
Avinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral arterial disease (PAD) in the United States and internationally. It develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures. The company's lumivascular products comprise Lightbox imaging consoles, as well as the Ocelot family of catheters, which are designed to allow physicians to penetrate a total blockage in an artery; and Pantheris, an image-guided atherectomy device that allows physicians to precisely remove arterial plaque in PAD patients. In addition, its first-generation chronic total occlusion (CTO)-crossing catheters, Wildcat and Kittycat 2, which employs a proprietary design that uses a rotational spinning technique allowing the physician to switch between passive and active modes when navigating across a CTO. Further, the company develops IMAGE-BTK for the treatment of PAD lesions below-the-knee. It markets and sells its products to interventional cardiologists, vascular surgeons, and interventional radiologists. Avinger, Inc. was incorporated in 2007 and is headquartered in Redwood City, California.
Wed, 05 Feb 2025
Avinger Inc shareholders approve liquidation plan - Investing.com
Mon, 27 Jan 2025
Avinger Announces Issuance of New U.S. Patent and Receives Notices of Allowance for Five Additional U.S. Patents - ACCESS Newswire
Fri, 24 Jan 2025
Avinger Inc adjourns Special Meeting due to lack of quorum - MSN
Tue, 24 Dec 2024
This Healthcare Stock Massively Outperformed The Market Before The Holiday - The Globe and Mail
Tue, 24 Dec 2024
TSLA, AVGR, JTAI, TEVA, NFLX: Top 5 Trending Stocks Today - Jet AI (NASDAQ:JTAI), Avinger (NASDAQ:AVGR) - Benzinga
Thu, 19 Dec 2024
Avinger’s 2024 Stockholder Meeting and Director Elections - TipRanks
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Medical - Instruments & Supplies
|
|
Shares Out | 0 (M) |
Shares Float | 3 (M) |
Held by Insiders | 1.88e+006 (%) |
Held by Institutions | 13.6 (%) |
Shares Short | 93 (K) |
Shares Short P.Month | 0 (K) |
EPS | -1.755e+007 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 0 |
Profit Margin | -260.9 % |
Operating Margin | -223.5 % |
Return on Assets (ttm) | -65.3 % |
Return on Equity (ttm) | -3 % |
Qtrly Rev. Growth | 7.43e+006 % |
Gross Profit (p.s.) | -8.19 |
Sales Per Share | 286.71 |
EBITDA (p.s.) | 1.27586e+006 |
Qtrly Earnings Growth | -8.8 % |
Operating Cash Flow | 0 (M) |
Levered Free Cash Flow | -15 (M) |
PE Ratio | -0.01 |
PEG Ratio | 0 |
Price to Book value | 0 |
Price to Sales | 0 |
Price to Cash Flow | -0.12 |
Dividend | 0 |
Forward Dividend | 122400 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |